Ganirelix NMP is a combination of Ganirelix, a gonadotropin-releasing hormone (GnRH) antagonist, and N-Methyl-2-Pyrrolidone (NMP), a pharmaceutical solubilising agent that enhances the stability and bioavailability of the formulation. Ganirelix works by competitively blocking GnRH receptors in the pituitary gland, rapidly suppressing the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) without causing an initial hormone flare. 

This prevents premature ovulation during controlled ovarian stimulation in women undergoing assisted reproductive technology (ART) such as IVF or ICSI. NMP acts as a solubiliser in the formulation, improving the solubility and delivery of Ganirelix for consistent subcutaneous administration.

Orgalutran 0.25mg Injection is used for:

• Prevention of premature LH surges during controlled ovarian stimulation in women undergoing ART such as IVF or ICSI.

• Suppression of endogenous gonadotropin release to allow controlled and timed egg maturation and retrieval.

Ganirelix NMP is administered as a subcutaneous injection, typically into the upper thigh or abdomen. It is usually started on Day 5 or 6 of controlled ovarian stimulation with gonadotropins and continued once daily until the day of the human chorionic gonadotropin (hCG) trigger injection, as directed by the treating fertility specialist.

It is important to consult a reproductive specialist before use, especially if you have any existing medical conditions or are taking other medications. Follow the prescribed dose and administration schedule carefully. Do not self-administer without proper training from your doctor or nurse on injection technique and site rotation.

Common side effects:

• Injection site reactions (redness, swelling, or bruising)

• Nausea

• Headache

• Abdominal discomfort or bloating

• Pelvic pain

Serious side effects (seek medical attention immediately if you experience):

• Signs of ovarian hyperstimulation syndrome (OHSS) such as severe abdominal pain, rapid weight gain, or difficulty breathing

• Severe allergic reactions (rash, swelling of the face or throat, difficulty breathing)

• Ectopic pregnancy signs (sharp pelvic pain with bleeding)

• Consult a Doctor Before Use: Especially if you have a history of allergic reactions to GnRH analogues, latex sensitivity, kidney disease, or any active hormonal disorders.

• Risk of OHSS: Women undergoing controlled ovarian stimulation are at risk of ovarian hyperstimulation syndrome. Monitor closely for early signs and report them to your doctor immediately.

• Ectopic Pregnancy Risk: Women with a history of ectopic pregnancy or tubal disease should be monitored carefully during and after fertility treatment.

• Caution in Pregnancy and Breastfeeding: Ganirelix NMP must not be used during pregnancy or breastfeeding. It is indicated only during the pre-conception phase of fertility treatment.

• Latex Sensitivity: The packaging of some Ganirelix formulations may contain latex components; inform your doctor if you have a known latex allergy.

• Use Ganirelix NMP with caution in women with known hypersensitivity to GnRH or its analogues, a history of allergic conditions, or impaired kidney function.

• Administer only under the supervision of a fertility specialist with experience in ART procedures.

• Regular ultrasound and hormonal monitoring throughout the stimulation cycle is essential to ensure safe and effective use.

• Do not adjust the dose or timing of Ganirelix NMP without consulting your fertility specialist, as this may affect treatment outcomes and egg maturation.

• Follow Your Clinic Protocol Precisely: Administer Orgalutran 0.25mg Injection at the same time each day as directed by your fertility clinic for consistent hormone suppression.

• Rotate Injection Sites: Alternate between thighs and abdomen to avoid skin irritation or lumps at the injection site.

• Monitor for OHSS: Report any sudden bloating, abdominal pain, or rapid weight gain to your doctor immediately, as these may be early signs of ovarian hyperstimulation.

• Stay Hydrated: Drink adequate water throughout your stimulation cycle to support overall wellbeing and reduce the risk of OHSS.

• Attend All Monitoring Appointments: Regular ultrasound and hormone monitoring during your cycle is essential to ensure safe and effective treatment with Orgalutran 0.25mg Injection.

1. European Medicines Agency. Orgalutran (Ganirelix) Summary of Product Characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/orgalutran

2. CDSCO Online. Ganirelix Acetate Injection. https://cdscoonline.gov.in/CDSCO/cdscoDrugs

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.